Cancer Therapy News and Research

RSS

Discovery of novel approach to suppress prostate cancer progression

Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models.

24 Nov 2008

Brookhaven scientists receive patent for improved cancer therapy device

Four physicists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory have been awarded U.S. Patent No. 7,432,516 B2 for the design of a "medical synchrotron" capable of delivering precision doses of proton radiation to cancerous tumors with minimal damage to surrounding healthy tissue.

24 Nov 2008

Lung cancer facts

Lung cancer kills more than four times as many Americans as breast cancer. But while pink ribbons trumpet Breast Cancer Awareness Month throughout October, little attention is paid to lung cancer in November, which is that disease's awareness month.

21 Nov 2008

Bionovo to present phase 1B trial results of BZL101 in metastatic breast cancer

Bionovo, Inc. has announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth International Conference in Atlanta, Georgia.

20 Nov 2008

Nanoparticle reports on drug delivery to breast tumors, predicts response to therapy

One of the hallmarks of many nanoparticle-based anticancer therapeutics and imaging agents is that they accumulate in tumors thanks to the fact that they are small enough to escape from the bloodstream through the leaky blood vessels that surround tumors.

20 Nov 2008

Survival of head and neck cancer patients is greatly affected by coexisting ailments

Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.

19 Nov 2008

Cytori announces seven new investigator-initiated clinical studies in Japan

All seven studies are investigator-initiated and to be performed under local and country guidelines. Cytori, who will not sponsor these studies, will continue work with country authorities, such as the Ministry of Health and Labor in Japan, to obtain specific regulatory approvals for its products.

19 Nov 2008

REOLYSIN shown to benefit some sarcoma patients

New data shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their lives.

19 Nov 2008

Nontoxic nanoparticle delivers and tracks drugs

A nontoxic nanoparticle developed by Penn State researchers is proving to be an all-around effective delivery system for both therapeutic drugs and the fluorescent dyes that can track their delivery.

18 Nov 2008

Doctors hesitant to discuss options to preserve fertility with cancer patients

Although some teenagers and young adults become infertile following cancer treatment, physicians are hesitant to discuss options to preserve fertility with patients, according to a new Florida study.

18 Nov 2008

Discovery of 13 new tumor-suppressor genes in liver cancer

Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise.

18 Nov 2008

Latina women more likely to regret breast cancer treatment decisions

Latina women who prefer speaking Spanish are more likely than other ethnic groups to express regret or dissatisfaction with their breast cancer treatment, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center.

18 Nov 2008

Study helps clarify role of vitamin D in cancer therapy

A colon cancer cell isn't a lost cause. Vitamin D can tame the rogue cell by adjusting everything from its gene expression to its cytoskeleton.

17 Nov 2008

Researchers find deadly protein that acts as a cancer master switch

Two critical properties of cancer cells are their ability to divide without restraint and to spread away from the primary tumor to establish new tumor sites.

17 Nov 2008

Scientists identify dangerous 'two-faced' protein crucial to breast cancer spread and growth

Two critical properties of cancer cells are their ability to divide without restraint and to spread away from the primary tumor to establish new tumor sites.

17 Nov 2008

CAPHOSOL shown to benefit cancer patients undergoing chemotherapy and radiation therapy

New data show that CAPHOSOL, an advanced electrolyte solution, results in low rates of oral mucositis and pain in patients with head and neck (HN) cancer who are undergoing chemotherapy and radiation therapy.

17 Nov 2008

Proton therapy may reduce serious side effect of lung cancer treatment

Patients with locally advanced lung cancer who receive chemotherapy and proton therapy, a specialized form a radiation therapy only available in a few centers in the United States, have fewer instances of a serious side effect called bone marrow toxicity than patients who receive chemotherapy and another type of radiation therapy called intensity modulated radiation therapy (IMRT), according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.

16 Nov 2008

PEA-15 protein points to potential targeted approach for ovarian cancer

A protein known to inhibit the growth of ovarian cancer works in part by forcing cancer cells to eat themselves until they die, researchers at The University of Texas M. D. Anderson Cancer Center report in the Nov. 15 issue of Cancer Research .

16 Nov 2008

Combination of carboplatin and paclitaxel with bevacizumab and cetuximab proves safe for lung cancer treatment

The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.

16 Nov 2008